Kemicetine

Kemicetine may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

UK matches:

• Kemicetine Succinate Injection (SPC)

Ingredient matches for Kemicetine

Chloramphenicol

Chloramphenicol is reported as an ingredient of Kemicetine in the following countries:

• India


• Indonesia


• Philippines


• Turkey

Chloramphenicol succinate sodium (a derivative of Chloramphenicol) is reported as an ingredient of Kemicetine in the following countries:

• Hong Kong


• Indonesia


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Discotrine

Discotrine may be available in the countries listed below.

Ingredient matches for Discotrine

Nitroglycerin

Nitroglycerin is reported as an ingredient of Discotrine in the following countries:

• Denmark


• France


• Iceland

International Drug Name Search

Periodent

Periodent may be available in the countries listed below.

Ingredient matches for Periodent

Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Periodent in the following countries:

• Argentina

International Drug Name Search

Remeron-S

Remeron-S may be available in the countries listed below.

Ingredient matches for Remeron-S

Mirtazapine

Mirtazapine is reported as an ingredient of Remeron-S in the following countries:

• Sweden

International Drug Name Search

Noodipina

Noodipina may be available in the countries listed below.

Ingredient matches for Noodipina

Nimodipine

Nimodipine is reported as an ingredient of Noodipina in the following countries:

• Brazil

International Drug Name Search

ReVia

Generic Name: naltrexone (oral) (nal TREX own)

Brand Names: ReVia

What is ReVia (naltrexone (oral))?

Naltrexone oral is an special narcotic drug that blocks the effects of other narcotic medicines and alcohol.

Naltrexone oral is used to treat narcotic drug or alcohol addiction..

Naltrexone oral may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about ReVia (naltrexone (oral))?

Your doctor may recommend that naltrexone oral be given to you by a family member or other caregiver. This is to make sure you are using the medicine as it was prescribed as part of your treatment.

Do not use narcotic drugs or alcohol while taking naltrexone oral. Never try to overcome the effects of the medication by taking large doses of narcotic drugs or alcohol. Doing so could result in dangerous effects, including coma and death. Ask your doctor before using any prescription or over-the-counter medicine to treat a cold, cough, diarrhea, or pain while taking naltrexone oral. These medicines may contain narcotics or alcohol. Naltrexone oral can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Carry an ID card or wear a medical alert bracelet stating that you are using naltrexone, in case of emergency. Any doctor, dentist, or emergency medical care provider who treats you should know that you are using this medication.

Additional forms of counseling and/or monitoring may be recommended during treatment with naltrexone oral.

What should I discuss with my health care provider before using ReVia (naltrexone (oral))?

Do not take this medicine if you are allergic to naltrexone, or if you have:

• 
  

  an addiction to narcotics;

  
  


• 
  

  a history of alcohol or narcotic drug use within the past 7-10 days; or

  
  


• 
  

  drug or alcohol withdrawal symptoms.

  
  

Before taking naltrexone, tell your doctor if you are allergic to any drugs, or if you have:

• kidney disease;


• liver disease; or


• a bleeding disorder such as hemophilia (if you are using naltrexone oral injection).

If you have any of these conditions, you may need a dose adjustment or special tests to safely take this medication.

FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether naltrexone oral passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use ReVia (naltrexone (oral))?

Use naltrexone oral exactly as it was prescribed for you. Do not use the medication in larger amounts or for longer than recommended by your doctor. Follow the directions on your prescription label.

Take the naltrexone oral tablet with a full glass of water. You may take the naltrexone oral tablet with food to decrease stomach upset.

It is important to take naltrexone oral regularly to get the most benefit.

Your doctor may recommend that naltrexone oral be given to you by a family member or other caregiver. This is to make sure you are using the medicine as it was prescribed as part of your treatment.

Carry an ID card or wear a medical alert bracelet stating that you are using naltrexone, in case of emergency. Any doctor, dentist, or emergency medical care provider who treats you should know that you are using this medication.

Additional forms of counseling and/or monitoring may be recommended during treatment with naltrexone oral.

Store naltrexone oral tablets at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and wait until your next regularly scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include nausea, stomach pain, dizziness, or seizure (convulsions).

What should I avoid while using ReVia (naltrexone (oral))?

Naltrexone oral can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Do not use narcotic drugs or alcohol while taking naltrexone oral. Never try to overcome the effects of the medication by taking large doses of narcotic drugs or alcohol. Doing so could result in dangerous effects, including coma and death. Ask your doctor before using any prescription or over-the-counter medicine to treat a cold, cough, diarrhea, or pain while taking naltrexone oral. These medicines may contain narcotics or alcohol.

ReVia (naltrexone (oral)) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using naltrexone oral and call your doctor at once if you have any of these serious side effects:

• 
  

  blurred vision or eye problems;

  
  


• 
  

  fast heartbeat;

  
  


• 
  

  mood changes, hallucinations (seeing or hearing things), confusion, thoughts of hurting yourself;

  
  


• 
  

  nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);

  
  


• 
  

  ear pain, ringing in your ears;

  
  


• 
  

  skin rash or itching; or

  
  


• 
  

  wheezing, difficulty breathing.

  
  

Less serious side effects may include:

• 
  

  feeling anxious, nervous, restless, or irritable;

  
  


• 
  

  feeling light-headed, fainting;

  
  


• 
  

  increased thirst;

  
  


• 
  

  muscle or joint aches;

  
  


• 
  

  weakness or tiredness;

  
  


• 
  

  sleep problems (insomnia); or

  
  


• 
  

  decreased sex drive, impotence, or difficulty having an orgasm.

  
  

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect ReVia (naltrexone (oral))?

The pain-relieving effects of any narcotic pain medications you use will be blocked if you use them during your treatment with naltrexone oral. Harmful side effects could also occur.

Before using naltrexone, tell your doctor if you use any of the following drugs:

• 
  

  buprenorphine (Buprenex, Subutex);

  
  


• 
  

  butorphanol (Stadol);

  
  


• 
  

  codeine (Tylenol with codeine);

  
  


• 
  

  hydrocodone (Lortab, Vicodin);

  
  


• 
  

  dezocine (Dalgan);

  
  


• 
  

  hydromorphone (Dilaudid);

  
  


• 
  

  levorphanol (Levo-Dromoran);

  
  


• 
  

  meperidine (Demerol);

  
  


• 
  

  methadone (Dolophine, Methadose);

  
  


• 
  

  morphine (Kadian, MS Contin, Roxanol);

  
  


• 
  

  nalbuphine (Nubain);

  
  


• 
  

  nalmefene (Revex);

  
  


• 
  

  naloxone (Narcan);

  
  


• 
  

  oxycodone (OxyContin, Roxicodone, Percocet);

  
  


• 
  

  oxymorphone (Numorphan); or

  
  


• 
  

  propoxyphene (Darvon, Darvocet).

  
  

This list it not complete and there may be other drugs that can interact with naltrexone oral. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

More ReVia resources

• ReVia Side Effects (in more detail)
• ReVia Dosage
• ReVia Use in Pregnancy & Breastfeeding
• Drug Images
• ReVia Drug Interactions
• ReVia Support Group
• 3 Reviews for ReVia - Add your own review/rating

• Naltrexone Prescribing Information (FDA)


• Naltrexone MedFacts Consumer Leaflet (Wolters Kluwer)


• Naltrexone Monograph (AHFS DI)


• Revia Advanced Consumer (Micromedex) - Includes Dosage Information


• Revia MedFacts Consumer Leaflet (Wolters Kluwer)


• Revia Prescribing Information (FDA)


• Vivitrol Prescribing Information (FDA)


• Vivitrol Advanced Consumer (Micromedex) - Includes Dosage Information


• Vivitrol Consumer Overview

Compare ReVia with other medications

• Alcohol Dependence
• Fibromyalgia
• Opiate Dependence
• Trichotillomania

Where can I get more information?

• Your pharmacist can provide more information about naltrexone.

See also: ReVia side effects (in more detail)

Lansoquilab

Lansoquilab may be available in the countries listed below.

Ingredient matches for Lansoquilab

Lansoprazole

Lansoprazole is reported as an ingredient of Lansoquilab in the following countries:

• Peru

International Drug Name Search

Arlidin

Arlidin may be available in the countries listed below.

Ingredient matches for Arlidin

Buphenine

Buphenine hydrochloride (a derivative of Buphenine) is reported as an ingredient of Arlidin in the following countries:

• India


• Mexico

International Drug Name Search

Bayer Copper Capsules 4 Grams

Bayer Copper Capsules 4 Grams may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Bayer Copper Capsules 4 Grams

Copper Oxide

Copper Oxide is reported as an ingredient of Bayer Copper Capsules 4 Grams in the following countries:

• New Zealand

International Drug Name Search

Lemblastine

Lemblastine may be available in the countries listed below.

Ingredient matches for Lemblastine

Vinblastine

Vinblastine sulfate (a derivative of Vinblastine) is reported as an ingredient of Lemblastine in the following countries:

• Chile

International Drug Name Search

Cereloid

Cereloid may be available in the countries listed below.

Ingredient matches for Cereloid

Dihydroergotoxine

Dihydroergotoxine mesilate (a derivative of Dihydroergotoxine) is reported as an ingredient of Cereloid in the following countries:

• India

International Drug Name Search

Eritropoyetina Alfa

Eritropoyetina Alfa may be available in the countries listed below.

Ingredient matches for Eritropoyetina Alfa

Epoetin Alfa

Epoetin Alfa is reported as an ingredient of Eritropoyetina Alfa in the following countries:

• Peru

International Drug Name Search

New Skelan

New Skelan may be available in the countries listed below.

Ingredient matches for New Skelan

Carisoprodol

Carisoprodol is reported as an ingredient of New Skelan in the following countries:

• Indonesia

Phenylbutazone

Phenylbutazone calcium salt (a derivative of Phenylbutazone) is reported as an ingredient of New Skelan in the following countries:

• Indonesia

International Drug Name Search

Nimutab

Nimutab may be available in the countries listed below.

Ingredient matches for Nimutab

Nimesulide

Nimesulide is reported as an ingredient of Nimutab in the following countries:

• India

International Drug Name Search

Dropgel

Dropgel may be available in the countries listed below.

Ingredient matches for Dropgel

Carbomer

Carbomer is reported as an ingredient of Dropgel in the following countries:

• Italy

International Drug Name Search

Polyflex

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Polyflex

Ampicillin

Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Polyflex in the following countries:

• United States

International Drug Name Search

Nitensum

Nitensum may be available in the countries listed below.

Ingredient matches for Nitensum

Nitrendipine

Nitrendipine is reported as an ingredient of Nitensum in the following countries:

• Chile

International Drug Name Search

Nemasol

Nemasol may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Nemasol

Levamisole

Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of Nemasol in the following countries:

• South Africa

International Drug Name Search

Bromperidol

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N05AD06

CAS registry number (Chemical Abstracts Service)

0010457-90-6

Chemical Formula

C21-H23-Br-F-N-O2

Molecular Weight

420

Therapeutic Category

Neuroleptic

Chemical Name

1-Butanone, 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-

Foreign Names

• Bromperidolum (Latin)
• Bromperidol (German)
• Brompéridol (French)
• Bromperidol (Spanish)

Generic Names

• Bromperidol (OS: USAN, DCIT, JAN, BAN)
• Brompéridol (OS: DCF)
• Azurene (IS)
• Bromoperidol (IS)
• CC 2489 (IS: Cilag)
• R 11333 (IS)
• Bromperidol (PH: BP 2010, Ph. Eur. 6)
• Brompéridol (PH: Ph. Eur. 6)
• Bromperidolum (PH: Ph. Eur. 6)
• Bromperidol Decanoate (OS: BANM, USAN)
• R 46541 (IS: Janssen)
• Brompéridol (décanoate de) (PH: Ph. Eur. 6)
• Bromperidol Decanoate (PH: BP 2010, Ph. Eur. 6)
• Bromperidoldecanoat (PH: Ph. Eur. 6)
• Bromperidoli Decanoas (PH: Ph. Eur. 6)

Brand Names

• Bromodol
  Janssen, Argentina



• Erodium
  Ivax, Argentina



• Impromen
  Formenti, Italy; Janssen, Belgium; Janssen, Luxembourg; Janssen, Netherlands; Janssen Pharmaceutical K.K., Japan



• Lunapron
  Kyowa Yakuhin, Japan



• Melkaick
  Shiono Kemikaru, Japan



• Preperidol
  Yoshindo, Japan



• Prindril
  Medisa Shinyaku, Japan



• Bromodol Decanoato
  Janssen, Argentina



• Impromen decanoas
  Janssen, Luxembourg; Janssen, Netherlands



• Impromen
  Janssen, Belgium



• Impromen Tropfen
  Janssen, Germany



• Tesoprel
  UCB, Germany

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Fixx

Fixx may be available in the countries listed below.

Ingredient matches for Fixx

Cefixime

Cefixime is reported as an ingredient of Fixx in the following countries:

• Vietnam

Cefixime trihydrate (a derivative of Cefixime) is reported as an ingredient of Fixx in the following countries:

• India

International Drug Name Search

Farmasal

Farmasal may be available in the countries listed below.

Ingredient matches for Farmasal

Aspirin

Acetylsalicylic Acid is reported as an ingredient of Farmasal in the following countries:

• Indonesia

International Drug Name Search

Bicef

Bicef may be available in the countries listed below.

Ingredient matches for Bicef

Cefadroxil

Cefadroxil is reported as an ingredient of Bicef in the following countries:

• Myanmar

International Drug Name Search

Ledar

Ledar may be available in the countries listed below.

Ingredient matches for Ledar

Tetracycline

Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Ledar in the following countries:

• Myanmar

International Drug Name Search

Cobainter

Cobainter may be available in the countries listed below.

Ingredient matches for Cobainter

Nicorandil

Nicorandil is reported as an ingredient of Cobainter in the following countries:

• Japan

International Drug Name Search

Nitrendilat

Nitrendilat may be available in the countries listed below.

Ingredient matches for Nitrendilat

Nitrendipine

Nitrendipine is reported as an ingredient of Nitrendilat in the following countries:

• Greece

International Drug Name Search

Advil

In the US, Advil (ibuprofen systemic) is a member of the drug class nonsteroidal anti-inflammatory agents and is used to treat Aseptic Necrosis, Back Pain, Costochondritis, Cystic Fibrosis, Dysautonomia, Fever, Frozen Shoulder, Gout - Acute, Headache, Muscle Pain, Osteoarthritis, Pain, Patent Ductus Arteriosus, Period Pain, Rheumatoid Arthritis, Sciatica and Temporomandibular Joint Disorder.

US matches:

• Advil


• Advil Allergy Sinus


• Advil Allergy Sinus Caplets


• Advil Cold and Sinus Caplets


• Advil Cold and Sinus Liqui-Gels


• Advil Liqui-Gels


• Advil PM


• Advil Childrens


• Advil Childrens Allergy Sinus


• Advil Cold & Sinus


• Advil Cold and Sinus


• Advil Cold and Sinus Liqui-Gel


• Advil Junior Strength


• Advil Liquigel


• Advil Migraine


• Advil Multi-Symptom Cold


• Advil Pediatric


• Advil Children's


• Advil Childrens Cold


• Advil Infants Concentrated Drops


• Advil PM Liqui-Gels

Ingredient matches for Advil

Ibuprofen

Ibuprofen is reported as an ingredient of Advil in the following countries:

• Australia


• Bahrain


• Bosnia & Herzegowina


• Brazil


• Canada


• Colombia


• Costa Rica


• Dominican Republic


• Ecuador


• El Salvador


• France


• Georgia


• Greece


• Guatemala


• Honduras


• Hungary


• Ireland


• Israel


• Luxembourg


• Mexico


• Netherlands


• Nicaragua


• Oman


• Panama


• Peru


• Philippines


• Poland


• Romania


• Slovakia


• Spain


• Turkey


• United States


• Venezuela

Pseudoephedrine

Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Advil in the following countries:

• Ireland


• Oman


• Poland

International Drug Name Search

Venutabs

Venutabs may be available in the countries listed below.

Ingredient matches for Venutabs

Troxerutin

Troxerutin is reported as an ingredient of Venutabs in the following countries:

• Switzerland

International Drug Name Search

Naox

Naox may be available in the countries listed below.

Ingredient matches for Naox

Oxytocin

Oxytocin is reported as an ingredient of Naox in the following countries:

• Brazil

International Drug Name Search

Furosemid Nordic Drugs

Furosemid Nordic Drugs may be available in the countries listed below.

Ingredient matches for Furosemid Nordic Drugs

Furosemide

Furosemide is reported as an ingredient of Furosemid Nordic Drugs in the following countries:

• Sweden

International Drug Name Search

Selgian

Selgian may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Selgian

Selegiline

Selegiline hydrochloride (a derivative of Selegiline) is reported as an ingredient of Selgian in the following countries:

• Belgium


• France


• Germany


• Italy


• Netherlands


• Portugal


• Switzerland


• United Kingdom

International Drug Name Search

Dime Time Extended Release

Generic Name: brompheniramine/phenylephrine/phenylpropanolamine (brome fen IR a meen/fen ill EFF rin/fen ill proe pa NOLE a meen)

Brand Names: Dime Time Extended Release

What is Dime Time Extended Release (brompheniramine/phenylephrine/phenylpropanolamine)?

Brompheniramine is an antihistamine. It works against the naturally occurring chemical histamine in your body. Brompheniramine prevents sneezing; itchy, watery eyes and nose; and other symptoms of allergies and hay fever.

Phenylephrine and phenylpropanolamine are decongestants. They constrict (shrink) blood vessels (veins and arteries). This reduces the blood flow to certain areas and allows nasal passages to open up.

Brompheniramine/phenylephrine/phenylpropanolamine is used to treat nasal congestion and sinusitis (inflammation of the sinuses) associated with allergies, hay fever, and the common cold.

Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.

Brompheniramine/phenylephrine/phenylpropanolamine may also be used for purposes other than those listed in this medication guide.

What is the most important information I should know about Dime Time Extended Release (brompheniramine/phenylephrine/phenylpropanolamine)?

Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.

Use caution when driving, operating machinery, or performing other hazardous activities. Brompheniramine/phenylephrine/phenylpropanolamine may cause dizziness or drowsiness. If you experience dizziness or drowsiness, avoid these activities. Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while taking brompheniramine/phenylephrine/phenylpropanolamine.

Do not take more of this medication than is recommended. If your symptoms do not improve, or if they worsen, talk to your doctor.

Who should not take Dime Time Extended Release (brompheniramine/phenylephrine/phenylpropanolamine)?

Do not take brompheniramine/phenylephrine/phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Before taking this medication, tell your doctor if you have

• kidney disease,


• liver disease,


• 
  

  diabetes,

  
  


• 
  

  glaucoma,

  
  


• 
  

  any type of heart disease or high blood pressure,

  
  


• 
  

  thyroid disease,

  
  


• 
  

  emphysema or chronic bronchitis, or

  
  


• 
  

  difficulty urinating or an enlarged prostate.

  
  

You may not be able to take brompheniramine/phenylephrine/phenylpropanolamine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.

Brompheniramine/phenylephrine/phenylpropanolamine is in the FDA pregnancy category B. This means that it is unlikely to harm an unborn baby. Do not take this medication without first talking to your doctor if you are pregnant. This medication passes into breast milk and may harm a nursing baby. Do not take this medication without first talking to your doctor if you are breast-feeding a baby. If you are over 65 years of age, you may be more likely to experience side effects from brompheniramine/phenylephrine/phenylpropanolamine. You may require a lower dose of this medication. Read the package label for directions or consult your doctor or pharmacist before treating a child with this medication. Children are more susceptible than adults to the effects of medicines and may have unusual reactions.

How should I take brompheniramine/phenylephrine/ phenylpropanolamine?

Take brompheniramine/phenylephrine/phenylpropanolamine exactly as directed. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Take each dose with a full glass of water. Do not crush, chew, or break the long-acting or sustained-release forms of this medication. Swallow them whole. If you are unsure about the formulation of your medicine, ask your pharmacist for help.

If you cannot swallow the tablets or capsules, look for a liquid form of the medication.

Do not take more of this medication than is recommended. An overdose of this medication can cause serious harm.

Do not take brompheniramine/phenylephrine/phenylpropanolamine for longer than 7 days in a row. If your symptoms do not improve, if they get worse, or if you have a fever, talk to your doctor.

Store brompheniramine/phenylephrine/phenylpropanolamine at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication.

What happens if I overdose?

Seek emergency medical attention.

Symptoms of a brompheniramine/phenylephrine/phenylpropanolamine overdose include a dry mouth, large pupils, flushing, nausea, and vomiting.

What should I avoid while taking Dime Time Extended Release (brompheniramine/phenylephrine/phenylpropanolamine)?

Use caution when driving, operating machinery, or performing other hazardous activities. Brompheniramine/phenylephrine/phenylpropanolamine may cause dizziness or drowsiness. If you experience dizziness or drowsiness, avoid these activities. Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while taking brompheniramine/phenylephrine/phenylpropanolamine.

Brompheniramine/phenylephrine/phenylpropanolamine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if brompheniramine/phenylephrine/phenylpropanolamine is taken with any of these medications.

Dime Time Extended Release (brompheniramine/phenylephrine/phenylpropanolamine) side effects

Serious side effects are unlikely to occur. Stop taking brompheniramine/phenylephrine/phenylpropanolamine and seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives).

Other, less serious side effects may be more likely to occur. Continue to take brompheniramine/phenylephrine/phenylpropanolamine and talk to your doctor or try another similar medication if you experience

• 
  

  dryness of the eyes, nose, and mouth;

  
  


• 
  

  drowsiness or dizziness;

  
  


• 
  

  blurred vision;

  
  


• 
  

  difficulty urinating; or

  
  


• 
  

  excitation in children.

  
  

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

What other drugs will affect Dime Time Extended Release (brompheniramine/phenylephrine/phenylpropanolamine)?

Do not take brompheniramine/phenylephrine/phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Do not take other over-the-counter cough, cold, allergy, diet, or sleep aids while taking brompheniramine/phenylephrine/phenylpropanolamine without first talking to your doctor or pharmacist. Other medications may also contain brompheniramine, phenylephrine, phenylpropanolamine, or other similar drugs. You may accidentally take too much of these medicines.

Brompheniramine/phenylephrine/phenylpropanolamine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if brompheniramine/phenylephrine/phenylpropanolamine is taken with any of these medications.

Drugs other than those listed here may also interact with brompheniramine/phenylephrine/phenylpropanolamine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.

More Dime Time Extended Release resources

• Dime Time Extended Release Drug Interactions
• 0 Reviews for Dime Time Extended Release - Add your own review/rating

Compare Dime Time Extended Release with other medications

• Cold Symptoms

Where can I get more information?

• Your pharmacist has additional information about brompheniramine/phenylephrine/ phenylpropanolamine written for health professionals that you may read.

What does my medication look like?

Brompheniramine/phenylephrine/phenylpropanolamine is available with a prescription under the brand names Bromophen T.D. and Tamine S.R. These medications contain 12 mg of brompheniramine, 15 mg of phenylephrine, and 15 mg of phenylpropanolamine. Other brand or generic formulations may also be available. Ask your pharmacist any questions you have about this medication, especially if it is new to you.

Dikmed

Dikmed may be available in the countries listed below.

Ingredient matches for Dikmed

Diclofenac

Diclofenac is reported as an ingredient of Dikmed in the following countries:

• Poland

International Drug Name Search

Arcapta

Arcapta is a brand name of indacaterol, approved by the FDA in the following formulation(s):

ARCAPTA NEOHALER (indacaterol maleate - powder; inhalation)

• 
  Manufacturer: NOVARTIS
  
  Approval date: July 1, 2011
  
  Strength(s): EQ 75MCG BASE ^[RLD]

Has a generic version of Arcapta been approved?

No. There is currently no therapeutically equivalent version of Arcapta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arcapta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Beta2-adrenoceptor agonists
  Patent 6,878,721
  Issued: April 12, 2005
  Inventor(s): Cuenoud; Bernard & Bruce; Ian & Fairhurst; Robin Alec & Beattie; David
  Assignee(s): Novartis AG
  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
  
  Patent expiration dates:
  
  
  • October 10, 2020
    
    ✓ 
    Patent use: THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 1, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Arcapta Consumer Information (Drugs.com)
• Arcapta Neohaler Consumer Information (Wolters Kluwer)
• Arcapta Neohaler inhalation Consumer Information (Cerner Multum)
• Arcapta Neohaler Advanced Consumer Information (Micromedex)
• Indacaterol Consumer Information (Wolters Kluwer)
• Indacaterol inhalation Consumer Information (Cerner Multum)
• Indacaterol Inhalation Advanced Consumer Information (Micromedex)

Lovastatina Teva

Lovastatina Teva may be available in the countries listed below.

Ingredient matches for Lovastatina Teva

Lovastatin

Lovastatin is reported as an ingredient of Lovastatina Teva in the following countries:

• Spain

International Drug Name Search

Nitrofurantoine CF

Nitrofurantoine CF may be available in the countries listed below.

Ingredient matches for Nitrofurantoine CF

Nitrofurantoin

Nitrofurantoin is reported as an ingredient of Nitrofurantoine CF in the following countries:

• Netherlands

International Drug Name Search

Glimepirid Winthrop

Glimepirid Winthrop may be available in the countries listed below.

Ingredient matches for Glimepirid Winthrop

Glimepiride

Glimepiride is reported as an ingredient of Glimepirid Winthrop in the following countries:

• Denmark


• Finland


• Germany


• Lithuania


• Slovenia

International Drug Name Search

Vetamox

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vetamox

Acetazolamide

Acetazolamide sodium salt (a derivative of Acetazolamide) is reported as an ingredient of Vetamox in the following countries:

• United States

International Drug Name Search

Flutamid-CT

Flutamid-CT may be available in the countries listed below.

Ingredient matches for Flutamid-CT

Flutamide

Flutamide is reported as an ingredient of Flutamid-CT in the following countries:

• Germany

International Drug Name Search

Laimolin

Laimolin may be available in the countries listed below.

Ingredient matches for Laimolin

Dequalinium Chloride

Dequalinium Chloride is reported as an ingredient of Laimolin in the following countries:

• Venezuela

International Drug Name Search

Minims Atropine Sulphate

Minims Atropine Sulphate may be available in the countries listed below.

Ingredient matches for Minims Atropine Sulphate

Atropine

Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Minims Atropine Sulphate in the following countries:

• Finland


• Malta


• New Zealand


• Oman


• South Africa

International Drug Name Search

Apo-Ramipril

Apo-Ramipril may be available in the countries listed below.

Ingredient matches for Apo-Ramipril

Ramipril

Ramipril is reported as an ingredient of Apo-Ramipril in the following countries:

• Canada

International Drug Name Search

Welchol

Welchol is a brand name of colesevelam, approved by the FDA in the following formulation(s):

WELCHOL (colesevelam hydrochloride - for suspension; oral)

• 
  Manufacturer: DAIICHI SANKYO
  
  Approval date: October 2, 2009
  
  Strength(s): 1.875GM/PACKET, 3.75GM/PACKET ^[RLD]

WELCHOL (colesevelam hydrochloride - tablet; oral)

• 
  Manufacturer: DAIICHI SANKYO
  
  Approval date: May 26, 2000
  
  Strength(s): 625MG ^[RLD]

Has a generic version of Welchol been approved?

No. There is currently no therapeutically equivalent version of Welchol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Welchol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Amine polymer sequestrant and method of cholesterol depletion
  Patent 5,607,669
  Issued: March 4, 1997
  Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen R.
  Assignee(s): GelTex Pharmaceuticals, Inc.
  An amine polymer includes first and second substituents bound to amines of the polymer. The first substituent includes a hydrophobic moiety. The second substituent includes a quaternary amine-containing moiety. A method for binding bile salts of bile acids in a mammal includes orally administering to the mammal a therapeutically-effective amount of the amine polymer.
  
  Patent expiration dates:
  
  
  • June 10, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT
  
  
  
  • June 10, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
  
  
  
  • December 10, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for removing bile salts from a patient with alkylated amine polymers
  Patent 5,679,717
  Issued: October 21, 1997
  Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
  Assignee(s): GelTex Pharmaceuticals, Inc.
  A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of product produced by a process comprising alkylating one or more crosslinked amine polymers, salts or copolymers thereof with at least one alkylating agent. The reaction product is characterized in that: (i) at least some of the nitrogen atoms are unreacted with alkylating agent; and (ii) less than 10 mol% of the nitrogen atoms in the polymer react with the alkylating agent to form quaternary ammonium units.
  
  Patent expiration dates:
  
  
  • April 29, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT
  
  
  
  • April 29, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
  
  
  
  • October 29, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Alkylated amine polymers
  Patent 5,693,675
  Issued: December 2, 1997
  Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
  Assignee(s): GelTex Pharmaceuticals Inc.
  The invention relates to alkylated amine polymers and a method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of product produced by a process comprising alkylating one or more crosslinked amine polymers, salts or copolymers thereof with at least one alkylating agent. The reaction product is characterized in that: (i) at least some of the nitrogen atoms are unreacted with alkylating agent; and (ii) less than 10 mol % of the nitrogen atoms in the polymer react with the alkylating agent to form quaternary ammonium units.
  
  Patent expiration dates:
  
  
  • December 2, 2014
    
  
  
  
  • December 2, 2014
    
    ✓ 
    Drug substance
  
  
  
  • June 2, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Process for removing bile salts from a patient and alkylated compositions therefor
  Patent 5,917,007
  Issued: June 29, 1999
  Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
  Assignee(s): GelTex Pharmaceuticals, Inc.
  The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer comprises the reaction product of polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent and a crosslinking agent.
  
  Patent expiration dates:
  
  
  • April 29, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT
  
  
  
  • April 29, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT
    ✓ 
    Drug substance
  
  
  
  • April 29, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
    ✓ 
    Drug substance
  
  
  
  • October 29, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Amine polymer sequestrant and method of cholesterol depletion
  Patent 5,919,832
  Issued: July 6, 1999
  Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
  Assignee(s): Geltex Pharmaceuticals Inc.
  An amine polymer includes first and second substituents bound to amines of the polymer. The first substituent includes a hydrophobic moiety. The second substituent includes a quaternary amine-containing moiety. A method for binding bile salts of bile acids in a mammal includes orally administering to the mammal a therapeutically-effective amount of the amine polymer.
  
  Patent expiration dates:
  
  
  • June 10, 2014
    
  
  
  
  • April 29, 2014
    
    ✓ 
    Drug substance
  
  
  
  • December 10, 2014
    
    ✓ 
    Pediatric exclusivity
  
  
  
  • October 29, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Process for removing bile salts from a patient and alkylated compositions therefor
  Patent 6,066,678
  Issued: May 23, 2000
  Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
  Assignee(s): GelTex Pharmaceuticals, Inc.
  The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer comprises the reaction product of polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent and a crosslinking agent.
  
  Patent expiration dates:
  
  
  • June 10, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT
  
  
  
  • April 29, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT
    ✓ 
    Drug substance
  
  
  
  • April 29, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
    ✓ 
    Drug substance
  
  
  
  • December 10, 2014
    
    ✓ 
    Pediatric exclusivity
  
  
  
  • October 29, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Process for removing bile salts from a patient and alkylated compositions therefor
  Patent 6,433,026
  Issued: August 13, 2002
  Inventor(s): W. Harry; Mandeville, III & Stephen Randall; Holmes-Farley
  Assignee(s): GelTex Pharmaceuticals, Inc.
  The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent.
  
  Patent expiration dates:
  
  
  • June 10, 2014
    
  
  
  
  • April 29, 2014
    
    ✓ 
    Drug substance
  
  
  
  • December 10, 2014
    
    ✓ 
    Pediatric exclusivity
  
  
  
  • October 29, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Process for removing bile salts from a patient and alkylated compositions therefor
  Patent 6,784,254
  Issued: August 31, 2004
  Inventor(s): W. Harry; Mandeville, III & Stephen Randall; Holmes-Farley
  Assignee(s): Genzyme Corporation
  The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent.
  
  Patent expiration dates:
  
  
  • April 29, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • October 29, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Process for removing bile salts from a patient and alkylated compositions therefor
  Patent 7,101,960
  Issued: September 5, 2006
  Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
  Assignee(s): Genzyme Corporation
  The invention relates to a method for reducing serum cholesterol in a patient in need thereof and alkylated and crosslinked poly(allylamine) polymers useful in the method. The alkylated and crosslinked poly(allylamine) polymers are crosslinked with epichlorohydrin and comprise at least some n-decyl substituted nitrogen atoms and at least some hexyltrimethyl ammonium substituted nitrogen atoms.
  
  Patent expiration dates:
  
  
  • April 29, 2014
    
    ✓ 
    Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • October 29, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for lowering serum glucose
  Patent 7,229,613
  Issued: June 12, 2007
  Inventor(s): Burke; Steven K. & Donovan; Joanne M.
  Assignee(s): Genzyme Corporation
  A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.
  
  Patent expiration dates:
  
  
  • April 17, 2022
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
  
  
  
  • April 17, 2022
    
    ✓ 
    Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
  
  
  
  • October 17, 2022
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 18, 2011 - FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
  
  
  • July 18, 2011 - PEDIATRIC EXCLUSIVITY
  
  
  • October 2, 2012 - REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
  
  
  • April 2, 2013 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Welchol Consumer Information (Wolters Kluwer)
• Welchol Suspension Consumer Information (Wolters Kluwer)
• Welchol Consumer Information (Cerner Multum)
• Welchol Advanced Consumer Information (Micromedex)
• WelChol AHFS DI Monographs (ASHP)
• Colesevelam Consumer Information (Wolters Kluwer)
• Colesevelam Suspension Consumer Information (Wolters Kluwer)
• Colesevelam Consumer Information (Cerner Multum)
• Colesevelam Advanced Consumer Information (Micromedex)
• Colesevelam Hydrochloride AHFS DI Monographs (ASHP)

Stenox

Stenox may be available in the countries listed below.

Ingredient matches for Stenox

Fluoxymesterone

Fluoxymesterone is reported as an ingredient of Stenox in the following countries:

• Mexico

International Drug Name Search

Nicotinell

Nicotinell may be available in the countries listed below.

UK matches:

• Nicotinell classic 2mg medicated chewing gum (SPC)
• Nicotinell classic 4mg medicated chewing gum (SPC)
• Nicotinell fruit 2mg medicated chewing gum (SPC)
• Nicotinell fruit 4mg medicated chewing gum (SPC)
• Nicotinell liquorice 2mg medicated chewing gum (SPC)
• Nicotinell liquorice 4mg medicated chewing gum (SPC)
• Nicotinell Mint 1mg Lozenge (SPC)
• Nicotinell Mint 2mg Lozenge (SPC)
• Nicotinell mint 2mg medicated chewing gum (SPC)
• Nicotinell mint 4mg medicated chewing gum (SPC)
• Nicotinell TTS 10 (SPC)
• Nicotinell TTS 20 (SPC)
• Nicotinell TTS 30 (SPC)

Ingredient matches for Nicotinell

Nicotine

Nicotine is reported as an ingredient of Nicotinell in the following countries:

• Argentina


• Austria


• Bahrain


• Belgium


• Chile


• Czech Republic


• Denmark


• Egypt


• Estonia


• Finland


• Germany


• Ghana


• Greece


• Guyana


• Hungary


• Iceland


• Iraq


• Ireland


• Israel


• Jordan


• Kenya


• Kuwait


• Latvia


• Lebanon


• Libya


• Lithuania


• Luxembourg


• Malaysia


• Netherlands


• New Zealand


• Nigeria


• Norway


• Oman


• Poland


• Qatar


• Saudi Arabia


• Singapore


• Spain


• Sudan


• Sweden


• Taiwan


• Tanzania


• Thailand


• Tunisia


• Turkey


• United Arab Emirates


• United Kingdom


• Yemen


• Zimbabwe

Nicotine bitartrate dihydrate (a derivative of Nicotine) is reported as an ingredient of Nicotinell in the following countries:

• Austria


• Finland


• Germany


• Hungary


• Iceland


• Netherlands


• Spain


• Sweden


• United Kingdom

Nicotine resinate (a derivative of Nicotine) is reported as an ingredient of Nicotinell in the following countries:

• Austria


• Belgium


• Estonia


• Finland


• Germany


• Iceland


• Portugal


• Spain


• Sweden


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

DBL Acetylcysteine

DBL Acetylcysteine may be available in the countries listed below.

Ingredient matches for DBL Acetylcysteine

Acetylcysteine

Acetylcysteine is reported as an ingredient of DBL Acetylcysteine in the following countries:

• Australia


• New Zealand

International Drug Name Search

Lovastatina Juventus

Lovastatina Juventus may be available in the countries listed below.

Ingredient matches for Lovastatina Juventus

Lovastatin

Lovastatin is reported as an ingredient of Lovastatina Juventus in the following countries:

• Spain

International Drug Name Search

Natriumiodid SAD

Natriumiodid SAD may be available in the countries listed below.

Ingredient matches for Natriumiodid SAD

Sodium Iodide

Sodium Iodide is reported as an ingredient of Natriumiodid SAD in the following countries:

• Denmark

International Drug Name Search

Nograine

Nograine may be available in the countries listed below.

Ingredient matches for Nograine

Sumatriptan

Sumatriptan succinate (a derivative of Sumatriptan) is reported as an ingredient of Nograine in the following countries:

• Mexico

International Drug Name Search

Sandoz Metformin

Sandoz Metformin may be available in the countries listed below.

Ingredient matches for Sandoz Metformin

Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Sandoz Metformin in the following countries:

• Canada


• South Africa

International Drug Name Search

Glucosamina Normon

Glucosamina Normon may be available in the countries listed below.

Ingredient matches for Glucosamina Normon

Glucosamine

Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Glucosamina Normon in the following countries:

• Spain

International Drug Name Search

NAC-1A Pharma

NAC-1A Pharma may be available in the countries listed below.

Ingredient matches for NAC-1A Pharma

Acetylcysteine

Acetylcysteine is reported as an ingredient of NAC-1A Pharma in the following countries:

• Germany

International Drug Name Search

Optiacid

Optiacid may be available in the countries listed below.

Ingredient matches for Optiacid

Famotidine

Famotidine is reported as an ingredient of Optiacid in the following countries:

• Vietnam

International Drug Name Search

Lacrystat

Lacrystat may be available in the countries listed below.

Ingredient matches for Lacrystat

Dextran

Dextran average molecular weight about 70000 (a derivative of Dextran) is reported as an ingredient of Lacrystat in the following countries:

• Belgium

Hypromellose

Hypromellose is reported as an ingredient of Lacrystat in the following countries:

• Belgium


• Luxembourg

International Drug Name Search

Ketotifen Stada

Ketotifen Stada may be available in the countries listed below.

Ingredient matches for Ketotifen Stada

Ketotifen

Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Ketotifen Stada in the following countries:

• Germany

International Drug Name Search

Nexium mups Paranova

Nexium mups Paranova may be available in the countries listed below.

Ingredient matches for Nexium mups Paranova

Esomeprazole

Esomeprazole magnesium, trihydrate (a derivative of Esomeprazole) is reported as an ingredient of Nexium mups Paranova in the following countries:

• Denmark

International Drug Name Search

Capsicum Farmaya

Capsicum Farmaya may be available in the countries listed below.

Ingredient matches for Capsicum Farmaya

Capsaicin

Capsaicin is reported as an ingredient of Capsicum Farmaya in the following countries:

• Spain

International Drug Name Search

Sterets H

Sterets H may be available in the countries listed below.

Ingredient matches for Sterets H

Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Sterets H in the following countries:

• Israel

International Drug Name Search

Rupock

Rupock may be available in the countries listed below.

Ingredient matches for Rupock

Pranoprofen

Pranoprofen is reported as an ingredient of Rupock in the following countries:

• Japan

International Drug Name Search

Nixol

Nixol may be available in the countries listed below.

Ingredient matches for Nixol

Pramipexole

Pramipexole is reported as an ingredient of Nixol in the following countries:

• Argentina

International Drug Name Search

Gothaplast

Gothaplast may be available in the countries listed below.

Ingredient matches for Gothaplast

Nonivamide

Nonivamide is reported as an ingredient of Gothaplast in the following countries:

• Germany

Salicylic Acid

Salicylic Acid is reported as an ingredient of Gothaplast in the following countries:

• Germany

International Drug Name Search

Coly-Mycin

Ingredient matches for Coly-Mycin

Colistin Sulfate

Colistin sulphomethate sodium (a derivative of Colistin) is reported as an ingredient of Coly-Mycin in the following countries:

• United States

International Drug Name Search

Selgin

Selgin may be available in the countries listed below.

Ingredient matches for Selgin

Selegiline

Selegiline hydrochloride (a derivative of Selegiline) is reported as an ingredient of Selgin in the following countries:

• India


• Poland

International Drug Name Search

Orhto M21

Orhto M21 may be available in the countries listed below.

Ingredient matches for Orhto M21

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Orhto M21 in the following countries:

• Japan

Norethisterone

Norethisterone is reported as an ingredient of Orhto M21 in the following countries:

• Japan

International Drug Name Search

Nomégestrol Biogaran

Nomégestrol Biogaran may be available in the countries listed below.

Ingredient matches for Nomégestrol Biogaran

Nomegestrol

Nomegestrol acetate (a derivative of Nomegestrol) is reported as an ingredient of Nomégestrol Biogaran in the following countries:

• France

International Drug Name Search

Bayro I.M.

Bayro I.M. may be available in the countries listed below.

Ingredient matches for Bayro I.M.

Etofenamate

Etofenamate is reported as an ingredient of Bayro I.M. in the following countries:

• Ecuador

International Drug Name Search

Torasemida Tarbis

Torasemida Tarbis may be available in the countries listed below.

Ingredient matches for Torasemida Tarbis

Torasemide

Torasemide is reported as an ingredient of Torasemida Tarbis in the following countries:

• Spain

International Drug Name Search

Metformine Pfizer

Metformine Pfizer may be available in the countries listed below.

Ingredient matches for Metformine Pfizer

Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Metformine Pfizer in the following countries:

• France

International Drug Name Search

Depakote

See also: Generic Depakote ER

Depakote is a brand name of divalproex sodium, approved by the FDA in the following formulation(s):

DEPAKOTE (divalproex sodium - capsule, delayed rel pellets; oral)

• 
  Manufacturer: ABBOTT
  
  Approval date: September 12, 1989
  
  Strength(s): EQ 125MG VALPROIC ACID ^[RLD][AB]

DEPAKOTE (divalproex sodium - tablet, delayed release; oral)

• 
  Manufacturer: ABBOTT
  
  Approval date: March 10, 1983
  
  Strength(s): EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[RLD][AB]


• 
  Manufacturer: ABBOTT
  
  Approval date: October 26, 1984
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB]

Has a generic version of Depakote been approved?

A generic version of Depakote has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Depakote and have been approved by the FDA:

divalproex sodium capsule, delayed rel pellets; oral

• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: January 23, 2009
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: March 28, 2011
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB]


• 
  Manufacturer: ZYDUS PHARMS USA INC
  
  Approval date: January 27, 2009
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB]

divalproex sodium tablet, delayed release; oral

• 
  Manufacturer: ANCHEN PHARMS
  
  Approval date: November 3, 2008
  
  Strength(s): EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA LTD
  
  Approval date: April 21, 2011
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: July 29, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: LUPIN
  
  Approval date: July 29, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: July 29, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: March 17, 2009
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: NU PHARM
  
  Approval date: July 29, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: ORCHID HLTHCARE
  
  Approval date: November 25, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: July 29, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: SUN PHARM INDS
  
  Approval date: July 29, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: July 29, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: UNICHEM LABS LTD
  
  Approval date: April 5, 2011
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: UPSHER SMITH
  
  Approval date: July 29, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: VINTAGE
  
  Approval date: November 30, 2009
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: WATSON LABS FLORIDA
  
  Approval date: February 25, 2011
  
  Strength(s): EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: WOCKHARDT
  
  Approval date: July 31, 2008
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]


• 
  Manufacturer: ZYDUS PHARMS USA INC
  
  Approval date: March 5, 2009
  
  Strength(s): EQ 125MG VALPROIC ACID ^[AB], EQ 250MG VALPROIC ACID ^[AB], EQ 500MG VALPROIC ACID ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Depakote. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Depakote.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 24, 2011 - EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
  
  
  • September 24, 2011 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Depakote Consumer Information (Drugs.com)
• Depakote Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Depakote Sprinkle Capsules Consumer Information (Wolters Kluwer)
• Depakote Consumer Information (Cerner Multum)
• Depakote Advanced Consumer Information (Micromedex)
• Divalproex Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Divalproex Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Divalproex Sprinkle Capsules Consumer Information (Wolters Kluwer)
• Divalproex sodium Consumer Information (Cerner Multum)
• Alti-Valproic Advanced Consumer Information (Micromedex)
• Depakote DR Advanced Consumer Information (Micromedex)
• Divalproex sodium Advanced Consumer Information (Micromedex)